Paper39256296
Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review.
Tan S and 8 others. Cardiovasc Toxicol, 2024. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review. Papers, record 39256296. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39256296
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immune Checkpoint Inhibitors | Major topic |
| Infliximab | Major topic |
| Lung Neoplasms | Major topic |
| Myocarditis | Major topic |
| Humans | |
| Carcinoma, Non-Small-Cell Lung | |
| Drug Resistance | |
| Interleukin-6 | |
| Treatment Outcome | |
| Tumor Necrosis Factor-alpha | |
| Interleukin-6 Inhibitors |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 92159302 | National Natural Science Foundation of China | PubMed | ||
| 82072598 | National Natural Science Foundation of China | PubMed | ||
| 2022ZDZX0018 | Science and Technology Project of Sichuan, China | PubMed | ||
| ZYGD22009 | 1-3-5 project for disciplines of excellence | PubMed | ||
| ZYJC21052 | 1-3-5 project for disciplines of excellence | PubMed |
Source PubMed
References93
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28363334 | Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges. | Drug Resist Updat | 2017 | https://conductscience.org/library/papers/28363334 | PubMed |
| 2 | 34724392 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/34724392 | PubMed |
| 3 | 29162153 | Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. | J Immunother Cancer | 2017 | https://conductscience.org/library/papers/29162153 | PubMed |
| 4 | 26765102 | Immune-related adverse events with immune checkpoint blockade: a comprehensive review. | Eur J Cancer | 2016 | https://conductscience.org/library/papers/26765102 | PubMed |
| 5 | 29802219 | Immune Checkpoint Inhibitor-Associated Myocarditis. | Oncologist | 2018 | https://conductscience.org/library/papers/29802219 | PubMed |
| 6 | 35692863 | Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. | Precis Clin Med | 2021 | https://conductscience.org/library/papers/35692863 | PubMed |
| 7 | 36270461 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2022 | https://conductscience.org/library/papers/36270461 | PubMed |
| 8 | 34172516 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34172516 | PubMed |
| 9 | 32135517 | NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. | J Natl Compr Canc Netw | 2020 | https://conductscience.org/library/papers/32135517 | PubMed |
| 10 | 29442540 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29442540 | PubMed |
| 11 | 31011325 | Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. | Case Rep Oncol | 2019 | https://conductscience.org/library/papers/31011325 | PubMed |
| 12 | 33785062 | Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series. | Cardiooncology | 2021 | https://conductscience.org/library/papers/33785062 | PubMed |
| 13 | 33298621 | Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/33298621 | PubMed |
| 14 | 38158463 | Effectiveness and safety of IL1 inhibition with anakinra in chronic refractory idiopathic myocarditis. | Intern Emerg Med | 2024 | https://conductscience.org/library/papers/38158463 | PubMed |
| 15 | 37305530 | Drug therapy for myocarditis induced by immune checkpoint inhibitors. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37305530 | PubMed |
| 16 | 31285688 | Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab. | Curr Oncol | 2019 | https://conductscience.org/library/papers/31285688 | PubMed |
| 17 | 32425357 | Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. | Ann Oncol | 2020 | https://conductscience.org/library/papers/32425357 | PubMed |
| 18 | 32093854 | Tocilizumab for Fulminant Programmed Death 1 Inhibitor-Associated Myocarditis. | J Thorac Oncol | 2020 | https://conductscience.org/library/papers/32093854 | PubMed |
| 19 | 35399037 | [Tocilizumab therapy for immune checkpoint inhibitor associated myocarditis: a case report]. | Zhonghua Xin Xue Guan Bing Za Zhi | 2022 | https://conductscience.org/library/papers/35399037 | PubMed |
| 20 | 36712142 | Steroid-Refractory Autoimmune Myocarditis after Pembrolizumab Therapy: Failure of Equine Anti-Thymocyte Globulin to Prevent Heart Failure. | J Clin Case Rep | 2019 | https://conductscience.org/library/papers/36712142 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42905219 | Cardiovascular Toxicity Across the Cancer Immunotherapy Spectrum: Mechanisms and Management in Immune Checkpoint Inhibitor (ICI) and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/42905219 | PubMed |
| 42839683 | A serum proteomics-based predictive model for steroid-resistant immune checkpoint inhibitor associated myocarditis. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42839683 | PubMed |
| 42591858 | Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42591858 | PubMed |
| 42499498 | Drug-induced adverse events in modern pharmacotherapy: mechanisms, clinical manifestations, and implications for risk assessment and management. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42499498 | PubMed |
| 41716314 | Immunotherapy-related cardiovascular toxicity: from mechanisms to management. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41716314 | PubMed |
| 41479885 | Beyond monoclonal antibodies: constraints and the case for alternative PD-1/PD-L1-targeting formats. | Front Immunol | 2025 | https://conductscience.org/library/papers/41479885 | PubMed |
| 41373794 | Fatal Myocarditis Following Adjuvant Immunotherapy: A Case Report and Literature Review. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41373794 | PubMed |
| 41141066 | Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, and Concern for 3-Ms Syndrome in a Patient With Metastatic Melanoma: A Case Report. | Cureus | 2025 | https://conductscience.org/library/papers/41141066 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39256296
GET https://conductscience.org/api/papers/v1/39256296/references?page=2